Key Facts
• August 25, 2025: U.S. health authorities suspend Ixchiq vaccine license.
• Four severe adverse reaction cases reported, including three individuals aged 70–82.
• Ixchiq, one of two FDA-approved chikungunya vaccines, was licensed in 2023.
• Chikungunya primarily affects tropical and subtropical regions but is spreading globally.
• Symptoms include high fever and joint pain, with severe cases rare but riskier for infants and elderly.
• WHO warned in July 2025 of pandemic risks due to climate change and mosquito spread.
• Europe recorded 27 chikungunya outbreaks in 2025, the highest on record.
• WHO noted similarities to a 2005 outbreak that affected 500,000 people worldwide.
Summary
The U.S. has suspended the license for the chikungunya vaccine Ixchiq following reports of severe adverse reactions, including four cases involving elderly individuals. Developed by French manufacturer Valneva and approved by the FDA in 2023, the vaccine’s safety is under review by European health authorities. Chikungunya, a mosquito-borne disease, is spreading beyond tropical regions due to climate change, raising concerns about a potential pandemic. Symptoms resemble dengue and Zika, with severe cases posing higher risks for vulnerable populations. The WHO has issued warnings about global outbreaks, citing parallels to a 2005 epidemic. Europe has already recorded 27 outbreaks in 2025, marking a record high.
